Table 4.
Percentage (±confidence limits) of TRPV1/neuropeptide DRG neurons in BTZ-treated rats.
| Acute BTZ-treatment | ||
|---|---|---|
| Ctrl | BTZ | |
| TRPV1/CGRP | 43.68 ± 0.06% (58 colocalized/87 TRPV1) |
49.43 ± 0.11% (43 colocalized/87 TRPV1) |
| CGRP/TRPV1 |
39.58 ± 0.10% (58 colocalized/96 CGRP) |
41.35 ± 0.01% (38 colocalized/104 CGRP) |
| TRPV1/SP | 43.53 ± 0.11% (37 colocalized/85 TRPV1) |
32.33 ± 0.06 %* (86 colocalized/266 TRPV1) |
| SP/TRPV1 | 35.92 ± 0.1% (37 colocalized/103 SP) |
44.10 ± 0.07%§
(86 colocalized/195 SP) |
|
| ||
| Chronic BTZ-treatment | ||
| Ctrl | BTZ | |
|
| ||
| TRPV1/CGRP | 43.86 ± 0.092% (50 colocalized/114 TRPV1) |
36.84 ± 0.11% (28 colocalized/76 TRPV1) |
| CGRP/TRPV1 | 36.76 ± 0.003% (50 colocalized/136 CGRP) |
27.72 ± 0.09%§§
(28 colocalized/101 CGRP) |
| TRPV1/SP | 43.33 ± 0.1% (39 colocalized/90 TRPV1) |
24.81 ± 0.07%** (33 colocalized/133 TRPV1) |
| SP/TRPV1 | 50.00 ± 0.006% (39 colocalized/78 SP) |
61.11 ± 0.13% (33 colocalized/54 SP) |
P value of ctrl rat versus BTZ-treated rat colocalization degree: § P = 0.090; §§ P = 0.072; *P ≤ 0.05; **P = 0.0016.